CAR T cells produced in vivo to treat cardiac injury
| Autor: | Joel G. Rurik, István Tombácz, Amir Yadegari, Pedro O. Méndez Fernández, Swapnil V. Shewale, Li Li, Toru Kimura, Ousamah Younoss Soliman, Tyler E. Papp, Ying K. Tam, Barbara L. Mui, Steven M. Albelda, Ellen Puré, Carl H. June, Haig Aghajanian, Drew Weissman, Hamideh Parhiz, Jonathan A. Epstein |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Heart Failure
Male Receptors Chimeric Antigen Multidisciplinary Heart Diseases Myocardium T-Lymphocytes Membrane Proteins Fibroblasts CD5 Antigens Adoptive Transfer Fibrosis Immunotherapy Adoptive Trogocytosis Mice Inbred C57BL Mice HEK293 Cells Endopeptidases Liposomes Animals Humans Nanoparticles RNA Messenger Cell Engineering Spleen |
| Zdroj: | Science. 375:91-96 |
| ISSN: | 1095-9203 0036-8075 |
| Popis: | Making CAR T cells in vivo Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |